´ëÇÑ´ç´¢º´ÇÐȸ The 21st Postgraduate Course of Diabetes : 2022-11-20±³À°ÀÏÀÚ : 2022-11-20
±³À°Àå¼Ò : ¿¬¼¼´ëÇб³ ¿¡ºñ½¼ÀÇ»ý¸í¿¬±¸¼¾ÅÍ À¯ÀÏÇÑȦ
±³À°ÁÖÁ¦ :
The 21st Postgraduate Course of DiabetesÁÖÃÖ±â°ü : ´ëÇÑ´ç´¢º´ÇÐȸ
´ã´çÀÚ : ±èÁ¤Èñ
¿¬¶ôó : 02-714-9081
À̸ÞÀÏ :
diabetes@kams.or.kr ±³À°Á¾·ù : ³»°ú
Âü¼®¿¹»óÀοø : 200¸í
Èñ¸ÁÆòÁ¡ : 5Á¡
Áö¿ª :
¼¿ïƯº°½Ã±³À°½Ã°£ : 6 ½Ã°£ 10ºÐ
¼¼ºÎ¼ö°·á : 70,000¿ø
ºñ°í »çÀüµî·Ï(ºñȸ¿ø): ÀÇ»ç(Àü°øÀÇÁ¦¿Ü)- 6¸¸¿ø, Àü°øÀÇ ¹× ºñÀÇ»ç- 4¸¸¿ø / »çÀüµî·Ï(ȸ¿ø): ÀÇ»ç(Àü°øÀÇÁ¦¿Ü)- 4¸¸¿ø, ºñÀÇ»ç- 2¸¸¿ø, Àü°øÀÇȸ¿ø- ¹«·á / ÇöÀåµî·Ï(ºñȸ¿ø): ÀÇ»ç(Àü°øÀÇÁ¦¿Ü)- 7¸¸¿ø, Àü°øÀÇ ¹× ºñÀÇ»ç- 5¸¸¿ø / ÇöÀåµî·Ï(ȸ¿ø): ÀÇ»ç(Àü°øÀÇÁ¦¿Ü)- 5¸¸¿ø, Àü°øÀÇ ¹× ºñÀÇ»ç- 3¸¸¿ø (¿Â¶óÀÎ ¼ö° ¾øÀ½)
±¸ºÐ ¿ùÀÏ °ÀÇ½Ç ½Ã°£ ±³À°Á¦¸ñ °»ç¸í(¼Ò¼Ó) Çʼö°ú¸ñ
±³À°½Ã°£ 11-20 À¯ÀÏÇÑȦ 09:00~09:20 Fundamentals of Diabetes : pathogenic mechanisms ±è´ëÁß(¾ÆÁÖÀÇ´ë)
±³À°½Ã°£ 11-20 À¯ÀÏÇÑȦ 09:20~09:40 Updates on Diabetes Diagnosis : changes in criteria ÀÌÀºÁ¤(¼º±Õ°üÀÇ´ë)
±³À°½Ã°£ 11-20 À¯ÀÏÇÑȦ 09:40~10:00 The development of guidelines in diabetes ±ÇÇõ»ó(°¡Å縯ÀÇ´ë)
Åä·Ð 11-20 À¯ÀÏÇÑȦ 10:00~10:25 Q&A °ûÀμ±, ¹ÚÁöÀ±, ±è´ë¿¬(ÀüºÏÀÇ´ë, Â÷ÀÇ°úÇдë, ¼øõÇâÀÇ´ë)
±³À°½Ã°£ 11-20 À¯ÀÏÇÑȦ 10:25~10:45 Understanding of MODY °û¼öÇå(¼¿ïÀÇ´ë)
±³À°½Ã°£ 11-20 À¯ÀÏÇÑȦ 10:45~11:05 The experience of LADA À̽Âȯ(°¡Å縯ÀÇ´ë)
±³À°½Ã°£ 11-20 À¯ÀÏÇÑȦ 11:05~11:25 How to detect immune-mediated type 1 diabetes Áø»ó¸¸(¼º±Õ°üÀÇ´ë)
Åä·Ð 11-20 À¯ÀÏÇÑȦ 11:25~11:50 Q&A À̹οµ, ±è¹ÎÁö, ±èÁö¹Î(¿¬¼¼ÀÇ´ë, °æºÏÀÇ´ë, Ãæ³²ÀÇ´ë)
±³À°½Ã°£ 11-20 À¯ÀÏÇÑȦ 12:40~12:55 ³»ºÐºñÀǻ簡 Á÷Á¢Çغ¸´Â º¹ºÎ ÃÊÀ½ÆÄ °Ë»çÀÇ ÀÇ¹Ì À±¼®±â(õ¾È¿£µµ³»°úÀÇ¿ø)
±³À°½Ã°£ 11-20 À¯ÀÏÇÑȦ 12:55~13:10 ³»ºÐºñÀǻ簡 Á÷Á¢Çغ¸´Â ½ÉÀå ÃÊÀ½ÆÄ °Ë»çÀÇ ÀÇ¹Ì À̼ºÈ(ÇູÇѾÆħ³»°úÀÇ¿ø)
±³À°½Ã°£ 11-20 À¯ÀÏÇÑȦ 13:10~13:30 Understanding of basic mechanism of metformin ÀÌ¿ëÈ£(¿¬¼¼ÀÇ´ë)
±³À°½Ã°£ 11-20 À¯ÀÏÇÑȦ 13:30~13:50 Differences of GLP-1/GIP combination montherapy Á¤Ã¢Èñ(¿ï»êÀÇ´ë)
±³À°½Ã°£ 11-20 À¯ÀÏÇÑȦ 13:50~14:10 DKA management focusing on the pathogenesis ±è»ó¿ë(Á¶¼±ÀÇ´ë)
Åä·Ð 11-20 À¯ÀÏÇÑȦ 14:10~14:35 Q&A ±è¹Î¿µ, ¹®ÁØÈ£, Á¶¿ëÀÎ(°æ»óÀÇ´ë, ¼¿ïÀÇ´ë, ÀÎÇÏÀÇ´ë)
±³À°½Ã°£ 11-20 À¯ÀÏÇÑȦ 14:45~15:05 Trials that present standard for glucose control ÀÌ¿ìÁ¦(¿ï»êÀÇ´ë)
±³À°½Ã°£ 11-20 À¯ÀÏÇÑȦ 15:05~15:25 Comparison of CVOTs of incretin-based therapy Á¶¿µ¹Î(¼¿ïÀÇ´ë)
±³À°½Ã°£ 11-20 À¯ÀÏÇÑȦ 15:25~15:45 What we learn SGLT2 inhibitor trials? ±è½Å°ï(°í·ÁÀÇ´ë)
Åä·Ð 11-20 À¯ÀÏÇÑȦ 15:45~16:10 Q&A ±Ç½½±â, Á¶Á¤È¯, ÃÖ¿ø¼®(À»ÁöÀÇ´ë, ¼º±Õ°üÀÇ´ë, Àü³²ÀÇ´ë)